HDAC inhibition prevents transgene expression downregulation and loss-of-function in T-cell-receptor-transduced T cells
- PMID: 33614916
- PMCID: PMC7878989
- DOI: 10.1016/j.omto.2021.01.014
HDAC inhibition prevents transgene expression downregulation and loss-of-function in T-cell-receptor-transduced T cells
Abstract
T cells that are gene-modified with tumor-specific T cell receptors are a promising treatment for metastatic melanoma patients. In a clinical trial, we treated seven metastatic melanoma patients with autologous T cells transduced to express a tyrosinase-reactive T cell receptor (TCR) (TIL 1383I) and a truncated CD34 molecule as a selection marker. We followed transgene expression in the TCR-transduced T cells after infusion and observed that both lentiviral- and retroviral-transduced T cells lost transgene expression over time, so that by 4 weeks post-transfer, few T cells expressed either lentiviral or retroviral transgenes. Transgene expression was reactivated by stimulation with anti-CD3/anti-CD28 beads and cytokines. TCR-transduced T cell lentiviral and retroviral transgene expression was also downregulated in vitro when T cells were cultured without cytokines. Transduced T cells cultured with interleukin (IL)-15 maintained transgene expression. Culturing gene-modified T cells in the presence of histone deacetylase (HDAC) inhibitors maintained transgene expression and functional TCR-transduced T cell responses to tumor. These results implicate epigenetic processes in the loss of transgene expression in lentiviral- and retroviral-transduced T cells.
Keywords: HDAC inhibitors; TCR-transduced T cells; cancer immunotherapy; cell therapy; functional responses; gene silencing; gene-modified T cells; sodium butyrate; transgene silencing; vorinostat.
© 2021 The Authors.
Conflict of interest statement
T.V.M. G.M.S., M.D., S.Y.W., A.V.D, C.R.W., K.A.H., J.J.S., C.V.G., C.F., J.F., T.M., M.T., D.M., B.D.C. B.A.F., and M.I.N. have no conflicts of interest to disclose. J.I.C. is on the speakers’ bureau for Bristol Meyers Squibb (BMS) and Merck; is a consultant for Clinigen; receives research support (to institution) from BMS, Prometheus, AVEO, and Roche/Genentech; and has a family member employed full time by BMS.
Figures






Similar articles
-
Clinical and immunologic evaluation of three metastatic melanoma patients treated with autologous melanoma-reactive TCR-transduced T cells.Cancer Immunol Immunother. 2018 Feb;67(2):311-325. doi: 10.1007/s00262-017-2073-0. Epub 2017 Oct 20. Cancer Immunol Immunother. 2018. PMID: 29052782 Free PMC article.
-
Costimulation of transduced T lymphocytes via T cell receptor-CD3 complex and CD28 leads to increased transcription of integrated retrovirus.Hum Gene Ther. 1999 Sep 1;10(13):2221-36. doi: 10.1089/10430349950017202. Hum Gene Ther. 1999. PMID: 10498253
-
T cell receptor (TCR) gene transfer with lentiviral vectors allows efficient redirection of tumor specificity in naive and memory T cells without prior stimulation of endogenous TCR.Hum Gene Ther. 2009 Dec;20(12):1576-88. doi: 10.1089/hum.2009.117. Hum Gene Ther. 2009. PMID: 19678763
-
CD8-independent tumor cell recognition is a property of the T cell receptor and not the T cell.J Immunol. 2003 Mar 1;170(5):2582-9. doi: 10.4049/jimmunol.170.5.2582. J Immunol. 2003. PMID: 12594285
-
Potential use of T cell receptor genes to modify hematopoietic stem cells for the gene therapy of cancer.Pathol Oncol Res. 1999;5(1):3-15. doi: 10.1053/paor.1999.0003. Pathol Oncol Res. 1999. PMID: 10079371 Review.
Cited by
-
Microbial short-chain fatty acids: a strategy to tune adoptive T cell therapy.J Immunother Cancer. 2022 Jul;10(7):e004147. doi: 10.1136/jitc-2021-004147. J Immunother Cancer. 2022. PMID: 35882448 Free PMC article. Review.
-
Entinostat, a histone deacetylase inhibitor, enhances CAR-NK cell anti-tumor activity by sustaining CAR expression.Front Immunol. 2025 Mar 7;16:1533044. doi: 10.3389/fimmu.2025.1533044. eCollection 2025. Front Immunol. 2025. PMID: 40124378 Free PMC article.
-
The Evolving T Cell Receptor Recognition Code: The Rules Are More Like Guidelines.Immunol Rev. 2025 Jan;329(1):e13439. doi: 10.1111/imr.13439. Immunol Rev. 2025. PMID: 39804137 Review.
-
Integrated vector genomes may contribute to long-term expression in primate liver after AAV administration.Nat Biotechnol. 2024 Aug;42(8):1232-1242. doi: 10.1038/s41587-023-01974-7. Epub 2023 Nov 6. Nat Biotechnol. 2024. PMID: 37932420 Free PMC article.
-
Harnessing the Gut Microbiota to Potentiate the Efficacy of CAR T Cell Therapy.Hemasphere. 2023 Aug 23;7(9):e950. doi: 10.1097/HS9.0000000000000950. eCollection 2023 Sep. Hemasphere. 2023. PMID: 37637993 Free PMC article. No abstract available.
References
-
- Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2020. CA Cancer J. Clin. 2020;70:7–30. - PubMed
-
- Rosenberg S.A., Packard B.S., Aebersold P.M., Solomon D., Topalian S.L., Toy S.T., Simon P., Lotze M.T., Yang J.C., Seipp C.A. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N. Engl. J. Med. 1988;319:1676–1680. - PubMed
-
- Duong C.P., Yong C.S., Kershaw M.H., Slaney C.Y., Darcy P.K. Cancer immunotherapy utilizing gene-modified T cells: From the bench to the clinic. Mol. Immunol. 2015;67(2 Pt A):46–57. - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources